Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2014. The report details a corporate action regarding a blocklisting application for the admission of new ordinary shares to the Official List of the London Stock Exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding share issuance rather than a financial performance report.
Material Changes
The material change reported is the application to the Financial Conduct Authority and the London Stock Exchange Plc for the admission of 50,000 Ordinary shares of 25p each. These shares are reserved under a block listing and will be issued pursuant to the GlaxoSmithKline plc Sharesave plan 2012.
Guidance, Outlook, and Risks
Admission of the shares is expected on March 19, 2014. Upon issuance, the new shares will rank pari passu with existing ordinary shares. The filing contains no management commentary on financial outlook, risks, contingencies, or unusual items.
Investor Verification Points
- Confirmation of the admission date for the 50,000 new shares (expected March 19, 2014).
- Verification that the shares are issued under the 2012 Sharesave plan.
- Confirmation that the new shares rank pari passu with existing ordinary shares.